Literature DB >> 26804596

The case for aflatoxins in the causal chain of gallbladder cancer.

Claudia Foerster1, Jill Koshiol2, Ariel R Guerrero3, Marcelo J Kogan3, Catterina Ferreccio4.   

Abstract

Chronic aflatoxin exposure has long been related to hepatocellular carcinoma (HCC). Recently, its association with gallbladder cancer (GBC) was postulated. Here we present the data supporting this hypothesis in Chile, the country with the highest GBC mortality worldwide with age-standardized mortality rates (ASMR) of 10.3 in women and 5.04 in men. The highest GBC rates occur in Southern Chile (ASMR=18), characterized by: high Amerindian ancestry, associated with high bile acid synthesis and gallstones; high poverty and high cereal agriculture, both associated with aflatoxin exposure. Aflatoxins have been detected in imported and locally grown foods items. We estimated population dietary exposure ranging from 0.25 to 35.0 ng/kg-body weight/day. The only report on human exposure in Chile found significantly more aflatoxin biomarkers in GBC than in controls (Odds Ratio=13.0). The hypothesis of aflatoxin-GBC causal link in the Chilean population is supported by: genetically-determined rapid cholesterol excretion and high gallstones prevalence (49.4%); low prevalence of HCC (ASMR=4.9) and low HBV infection (0.15%) the main co-factor of aflatoxins in HCC risk. If the association between aflatoxins and GBC were confirmed, public health interventions based on food regulation could have a substantial public health impact.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26804596     DOI: 10.1016/j.mehy.2015.11.026

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

1.  Association of Aflatoxin and Gallbladder Cancer.

Authors:  Jill Koshiol; Yu-Tang Gao; Michael Dean; Patricia Egner; Chirag Nepal; Kristine Jones; Bingsheng Wang; Asif Rashid; Wen Luo; Alison L Van Dyke; Catterina Ferreccio; Michael Malasky; Ming-Chang Shen; Bin Zhu; Jesper B Andersen; Allan Hildesheim; Ann W Hsing; John Groopman
Journal:  Gastroenterology       Date:  2017-04-17       Impact factor: 22.682

Review 2.  An overview on possible links between aflatoxin B1 exposure and gallbladder cancer.

Authors:  Jéssica Costa; Nelson Lima; Cledir Santos
Journal:  Mycotoxin Res       Date:  2021-05-21       Impact factor: 3.833

3.  Occurrence of relevant mycotoxins in food commodities consumed in Chile.

Authors:  Claudia Foerster; Katherine Muñoz; Lorena Delgado-Rivera; Andrea Rivera; Sandra Cortés; Andrea Müller; Gabriel Arriagada; Catterina Ferreccio; Gisela Rios
Journal:  Mycotoxin Res       Date:  2019-07-29       Impact factor: 3.833

Review 4.  Cancer of the gallbladder-Chilean statistics.

Authors:  Luis Villanueva
Journal:  Ecancermedicalscience       Date:  2016-12-21

Review 5.  Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico.

Authors:  Jacklyn M Nemunaitis; Ursa Brown-Glabeman; Heloisa Soares; Jessica Belmonte; Ben Liem; Itzhak Nir; Victor Phuoc; Rama R Gullapalli
Journal:  BMC Cancer       Date:  2018-06-18       Impact factor: 4.430

6.  Knowledge and Behavioral Habits to Reduce Mycotoxin Dietary Exposure at Household Level in a Cohort of German University Students.

Authors:  Katherine Muñoz; Mara Wagner; Florian Pauli; Juliane Christ; Gerhard Reese
Journal:  Toxins (Basel)       Date:  2021-10-26       Impact factor: 4.546

Review 7.  Environmental and Lifestyle Risk Factors in the Carcinogenesis of Gallbladder Cancer.

Authors:  Pablo Pérez-Moreno; Ismael Riquelme; Patricia García; Priscilla Brebi; Juan Carlos Roa
Journal:  J Pers Med       Date:  2022-02-08

8.  Assessment of Mycotoxin Exposure in a Rural County of Chile by Urinary Biomarker Determination.

Authors:  Claudia Foerster; Gisela Ríos-Gajardo; Patricia Gómez; Katherine Muñoz; Sandra Cortés; Carlos Maldonado; Catterina Ferreccio
Journal:  Toxins (Basel)       Date:  2021-06-25       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.